Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 14-Mar-24 5:01 PM View:  | Tagliaferri Mary Director | Y-Mabs Therapeutics, Inc. (YMAB) | 12-Mar-24 | Grant | 4,660 | -- | -- | 100% 0 to 4.66K | |
| 07-Mar-24 5:02 PM View: | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 1,711 | $16.53 | $28,282.80 | (4%) 39.87K to 38.16K | |
| 07-Mar-24 5:01 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 3,900 | $16.44 | $64,116.00 | (< 1%) 487.63K to 483.73K | |
| 07-Mar-24 4:59 PM View: | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 1,682 | $16.55 | $27,837.10 | (5%) 35.6K to 33.92K | |
| 14-Feb-24 4:30 PM View: | Rossi Michael J President & CEO Director | Y-Mabs Therapeutics, Inc. (YMAB) | 12-Feb-24 | Grant | 35,700 | -- | -- | 100% 0 to 35.7K | |
| 22-Jan-24 5:48 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 18,100 | -- | -- | 9% 192.78K to 210.88K | |
| 22-Jan-24 6:00 PM View: | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 5:54 PM View: | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 28% 63.46K to 81.26K | |
| 22-Jan-24 5:58 PM View: | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 5:56 PM View: | Wilms Joris SVP & CHIEF OPERATING OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 6:02 PM View: | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 81% 22.07K to 39.87K | |
| 22-Jan-24 5:52 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 22,100 | -- | -- | 5% 465.53K to 487.63K | |
| 26-Dec-23 4:15 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 21-Dec-23 | Option Exercise | 50,000 | $2.00 | $100,000.00 | 12% 415.53K to 465.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 15-Dec-23 | Sale | 50,000 | $6.61 | $330,500.00 | (11%) 465.53K to 415.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 14-Dec-23 | Sale | 50,000 | $6.83 | $341,500.00 | (10%) 515.53K to 465.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 13-Dec-23 | Sale | 50,000 | $6.58 | $329,000.00 | (9%) 565.53K to 515.53K | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Purchase Duplicate | 102,863 | $7.01 | $720,843.00 | 2% 4.45M to 4.55M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Purchase | 102,863 | $7.01 | $720,843.00 | 2% 4.45M to 4.55M | |
| 12-Dec-23 8:26 AM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Private Purchase Duplicate | 6,455 | $6.85 | $44,231.60 | < 1% 4.55M to 4.56M | |
| 12-Dec-23 8:27 AM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Private Purchase | 6,455 | $6.85 | $44,231.60 | < 1% 4.55M to 4.56M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Dec-23 | Purchase | 18,503 | $6.99 | $129,379.00 | < 1% 4.43M to 4.45M | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Dec-23 | Purchase Duplicate | 18,503 | $6.99 | $129,379.00 | < 1% 4.43M to 4.45M | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 07-Dec-23 | Private Purchase Duplicate | 6,183 | $6.50 | $40,189.50 | < 1% 4.43M to 4.43M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 07-Dec-23 | Private Purchase | 6,183 | $6.50 | $40,189.50 | < 1% 4.43M to 4.43M | |
| 01-Dec-23 5:14 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 29-Nov-23 | Private Purchase Duplicate | 51,837 | $5.97 | $309,477.00 | 1% 4.37M to 4.43M | |
| 01-Dec-23 5:15 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 29-Nov-23 | Private Purchase | 51,837 | $5.97 | $309,477.00 | 1% 4.37M to 4.43M | |
| 29-Nov-23 5:14 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Nov-23 | Purchase | 30,671 | $5.81 | $178,275.00 | < 1% 4.34M to 4.37M | |
| 29-Nov-23 5:15 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Nov-23 | Purchase Duplicate | 30,671 | $5.81 | $178,275.00 | < 1% 4.34M to 4.37M | |
| 29-Nov-23 5:15 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 27-Nov-23 | Private Purchase Duplicate | 62,516 | $5.49 | $343,019.00 | 1% 4.28M to 4.34M | |
| 29-Nov-23 5:14 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 27-Nov-23 | Private Purchase | 62,516 | $5.49 | $343,019.00 | 1% 4.28M to 4.34M | |
| 22-Nov-23 5:00 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 21-Nov-23 | Sale | 75,000 | $5.31 | $397,988.00 | (12%) 640.53K to 565.53K | |
| 22-Nov-23 5:00 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 20-Nov-23 | Sale | 75,000 | $5.30 | $397,395.00 | (10%) 715.53K to 640.53K | |
| 09-Jun-23 6:05 PM View: | Hamill Laura Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | 100% 0 to 2.33K | |
| 09-Jun-23 6:02 PM View: | Ber Gerard Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | 100% 0 to 2.33K | |
| 09-Jun-23 6:00 PM View: | Healy James Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | < 1% 2.22M to 2.22M | |
| 09-Jun-23 6:00 PM View: | Tyagi Ashu Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | 100% 0 to 2.33K | |
| 09-Jun-23 6:01 PM View: | Gill David N Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | 100% 0 to 2.33K | |
| 09-Jun-23 6:04 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Jun-23 | Grant | 2,330 | -- | -- | < 1% 4.28M to 4.28M | |
| 17-May-23 5:07 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 15-May-23 | Private Purchase Duplicate | 101,740 | $9.65 | $981,404.00 | 2% 4.18M to 4.28M | |
| 17-May-23 5:05 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 15-May-23 | Private Purchase | 101,740 | $9.65 | $981,404.00 | 2% 4.18M to 4.28M | |
| 19-Jan-23 4:39 PM View: | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 17,800 | -- | -- | 100% 0 to 17.8K | |
| 19-Jan-23 4:36 PM View: | Wilms Joris SVP & CHIEF OPERATING OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 17,800 | -- | -- | 100% 0 to 17.8K | |
| 19-Jan-23 4:42 PM View: | Gad Thomas See Remarks Director | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 40,500 | -- | -- | 6% 675.03K to 715.53K | |
| 19-Jan-23 4:45 PM View: | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 17,800 | -- | -- | 417% 4.27K to 22.07K | |
| 19-Jan-23 4:34 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 11,700 | -- | -- | 6% 181.08K to 192.78K | |
| 19-Jan-23 4:40 PM View: | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 17,800 | -- | -- | 100% 0 to 17.8K | |
| 19-Jan-23 4:44 PM View: | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 17-Jan-23 | Grant | 17,800 | -- | -- | 39% 45.66K to 63.46K | |
| 16-Nov-22 7:01 PM View: | Rajah Vignesh SVP & CMO | Y-Mabs Therapeutics, Inc. (YMAB) | 15-Nov-22 | Private Purchase | 1,195 | $4.92 | $5,884.18 | 39% 3.07K to 4.27K | |
| 23-Feb-22 10:00 PM View: | Kruse Bo EVP, CFO, Secretary & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 22-Feb-22 | Sale (Planned) | 4,000 | $7.85 | $31,400.00 | (2%) 185.08K to 181.08K | |
| 09-Feb-22 6:59 PM View: | Gad Thomas See Remarks Director | Y-Mabs Therapeutics, Inc. (YMAB) | 09-Feb-22 | Sale | 64,276 | $6.96 | $447,117.00 | (9%) 739.31K to 675.03K |
